News News October 10, 2017 On the 22nd September 2017 Granules OmniChem Limited (GOC) received the Establishment Inspection Report (EIR) from the US-FDA Read more October 1, 2017 Louvain-la-Neuve: New address from 01/10/2017 Read more September 19, 2017 Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency and Antibody Drug Conjugate Commercial Facility Read more August 24, 2017 Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line Read more July 24, 2017 CEO J. David Enloe Awarded ‘Most Admired CEO’ Read more April 14, 2017 Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing Read more April 13, 2017 Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing Read more December 18, 2016 Ajinomoto Group Acquires All Shares of GeneDesign, a Nucleic Acid Drug CDMO, to Accelerate Expansion of the Contract Business for Oligonucleotides. Read more October 4, 2016 Biologics candidate manufactured using Ajinomoto Co., Inc.’s CORYNEX® Protein Expression System enters clinical trials for the first time Read more May 17, 2016 Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies Read more March 15, 2016 Ajinomoto Althea, Inc. Expands Its Capacity of Fill Finish Manufacturing with Addition of Second Shift Read more December 10, 2015 Ajinomoto Althea, Inc. Launches Process and Analytical Development Services for Antibody Drug Conjugates (ADCs) Therapeutics Read more Loading…Load More Althea Technologies Announces Expanded Roles for Key Executives Previous Page 1 … 6 7 8